Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of Net Margin data on file, last reported at 136.03% in Q1 2026.

• On a quarterly basis, Net Margin fell 2740.0% year-over-year to 136.03% in Q1 2026; TTM through Mar 2026 was 90.03%, a 237.0% increase from a year earlier, with the FY2025 full-year figure at 84.55%, up 1635.0% from the prior year.
• Net Margin for Q1 2026 stood at 136.03%, down from 59.13% in the prior quarter.
• Over the last five years, Net Margin for RARE reached as high as 59.13% in Q4 2025 and fell as low as 270.23% in Q3 2022.
• Historically, Net Margin has averaged 133.13% across 5 years, with a median of 136.03% in 2026.
• Across the five-year window, Net Margin sank 54766 bps in 2022 and surged 10741 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 148.5% in 2022, then jumped by 35 bps to 97.17% in 2023, then advanced by 19 bps to 78.47% in 2024, then advanced by 25 bps to 59.13% in 2025, then sank by 130 bps to 136.03% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 136.03% in Q1 2026, 59.13% in Q4 2025, and 112.81% in Q3 2025.